Galectin (GALT) Reports Exploratory Phase 2a Pilot Trial of GR-MD-02 in Nash Misses Primary Biomarker Endpoint; Announces $1.5M Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St opens lower as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- US dollar briefly falls vs yen after GDP data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
H.C. Wainwright Downgrades Galectin Therapeutics (GALT) to Neutral
September 29, 2016 7:06 AM EDTH.C. Wainwright downgraded Galectin Therapeutics (NASDAQ: GALT) from Buy to Neutral with a price target of $1.50 (from $8.00) after the company reported that the Phase 2 NASH-FX trial missed its primary endpoint, improvement in liver fibrosis measured by cT1 (LiverMultiScan), as well as both secondary endpoints, liver stiffness (a surrogate for fibrosis) as measured by magnetic resonance elastography (MRE) and FibroScan.
Analyst Ed Arce commented, "This unequivocal... More
Galectin Therapeutics (GALT) to Resume Trading at 4:45PM ET
September 27, 2016 4:24 PM EDTGalectin Therapeutics (NASDAQ: GALT) to resume trading at 4:45PM following study failure.
... MoreGalectin Therapeutics (GALT) Agrees to Sell 1.5M Convertible Preferred Shares
September 27, 2016 4:18 PM EDTGalectin Therapeutics (NASDAQ: GALT) disclosed that on September 22, 2016 it entered into a Securities Purchase Agreement with 10X Fund, L.P., a Delaware limited partnership (Purchaser). Pursuant to the Purchase Agreement, the Company has agreed to issue and sell to Purchaser, and Purchaser has agreed to purchase from the Company at closings held or to be held on September 22, 2016 and September 29, 2016 (i)... More
Galectin Therapeutics (GALT) halted, news pending
September 27, 2016 4:06 PM EDTGalectin Therapeutics (NASDAQ: GALT) halted, news pending
... More
